Pharmaceuticals in the environment: Scientific evidence of risks and its regulation

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1656, 2014, Pages

  Küster, Anette ^a   Adler, Nicole ^a  

^a UMWELTBUNDESAMT   (Germany)

Author keywords

Emerging substances; Environmental risk assessment; Monitoring; Pharmaceuticals; Prioritization; Regulation

Indexed keywords

DRUG; ENVIRONMENTAL IMPACT ASSESSMENT; ENVIRONMENTAL RISK; POLLUTION CONTROL; POLLUTION EFFECT; POLLUTION POLICY; RISK ASSESSMENT;

GERMANY;

DRUG; POLLUTANT;

ADVERSE EFFECTS; ANIMAL; CHEMISTRY; DRUG LEGISLATION; ENVIRONMENTAL MONITORING; EUROPE; HUMAN; POLLUTANT; RISK ASSESSMENT;

ANIMALS; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; EUROPE; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84907821703     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0587     Document Type: Review

References (31)

1. Bergmann A, Fohrmann R, Weber FA. 2011 Zusammenstellung von Monitoringdaten zu Umweltkonzentrationen von Arzneimitteln. Texte Umweltbundesamt, p. 66. See http://www. umweltbundesamt. de/sites/default/files/medien/461/publikationen/4188. pdf.
2. Loos R et al. 2013 EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant effluents. Water Res. 47, 6475-6487. (doi: 10. 1016/j. watres. 2013. 08. 024).
3. Kostich MS, Batt AL, Lazorchak JM. 2014 Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ. Pollut. 184, 354-359. (doi: 10. 1016/j. envpol. 2013. 09. 013).
4. Liu JL, Wong MH. 2013 Pharmaceuticals and personal care products (PPCPs): a review on environmental contamination in China. Environ. Int. 59, 208-224. (doi: 10. 1016/j. envint. 2013. 06. 012).
5. Jobling S, Nolan M, Tyler CR, Brighty G, Sumpter JP. 1998 Widespread sexual disruption in wild fish. Environ. Sci. Technol. 32, 2498-2506. (doi: 10. 1021/es9710870).
6. Brausch JM, Connors KA, Brooks BW, Rand GM. 2012 Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing. Rev. Environ. Contam. Toxicol. 218, 1-99. (doi: 10. 1007/978-1-4614-3137-4_1).
7. Huerta B, Rodriguez-Mazaz S, Barcelo D. 2012 Pharmaceuticals in biota in the aquatic environment: analytical methods and environmental implications. Anal. Bioanal. Chem. 404, 2611-2624. (doi: 10. 1007/s00216-012-6144-y).
8. Metcalfe CD. 2013 Pharmaceutical contaminants of emerging concern in the environment. Environ. Toxicol. Chem. 32, 1683-1684. (doi: 10. 1002/etc. 2293).
9. Brodin T, Fick J, Johnsson M, Klaminder J. 2013 Dilute concentrations of a psychiatric drug alter behaviour of fish from natural populations. Science 339, 814-815. (doi: 10. 1126/science. 1226850).
10. Metcalfe CD, Chu S, Judt C, Li H, Oakes KD, Servos MR, Andres DM. 2010 Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environ. Toxicol. Chem. 29, 79-89. (doi: 10. 1002/etc. 27).
11. European Environment Agency 2010 Pharmaceuticals in the environment-results of an EEA workshop. EEA technical report no 1/2010. Luxembourg: Office for Official Publications of the European Communities.
12. European Commission 2010 Directive 2010/84/EU of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the community code relating to medicinal products for human use.
13. European Commission 2004 Directive 2004/27/EC of the European Parliament and of the Council amending Directive 2001/83/EC on the community code relating to medicinal products for human use.
14. European Commission 2004 Directive 2004/28/EC of the European Parliament and of the Council amending Directive 2001/82/EC on the community code relating to veterinary medicinal products.
15. European Medicines Agency 2000 Committee for Medicinal Products for Veterinary use (CVMP): guideline on environmental impact assessment (EIAS) for veterinary medicinal products phase I. CVMP/VICH/592/98.
16. European Medicines Agency 2003 Committee for Medicinal Products for Veterinary use (CVMP): guideline on environmental impact assessment for veterinary medicinal products phase II. CVMP/VICH/790/03.
17. European Medicines Agency 2008 Committee for Medicinal Products for Veterinary use (CVMP): revised guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL38. EMEA/CVMP/ERA/418282/2005-Rev. 1.
18. European Medicines Agency 2006 Committee for Medicinal Products for Human Use (CHMP): guideline on the environmental risk assessment of medicinal products for human use. EMEA/CHMP/SWP/4447/00.
19. Moermond CTA, Janssen MPM, de Knecht JA, Montforts MHMM, Peijnenburg WJGM, Zweers PGPC, Sijmy DTHM. 2011 PBT Assessment using the revised Annex XIII of REACH: a comparison with other regulatory frameworks. Integr. Environ. Assess. Manag. 8, 359-371. (doi: 10. 1002/ieam. 1248).
20. European Medicines Agency 2010 Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products. EMA/CVMP/ERAWP/409328/2010.
21. European Commission 2006 Directive 2006/118/EC of the European Parliament and of the Council on the protection of groundwater against pollution and deterioration. 2006/118/EC.
22. Sumpter JP. 2010 Pharmaceuticals in the environment: moving from a problem to a solution. In Green and sustainable pharmacy (eds K Kümmerer, M Hempel), pp. 11-22. Berlin, Germany: Springer.
23. European Commission 2000 Directive 2000/60/EC of the European Parliament and of the Council establishing a framework for community action in the field of water policy.
24. Roos V, Gunnarsson L, Fick J, Larsson DGJ, Ruden C. 2012 Prioritising pharmaceuticals for environmental risk assessment: towards adequate and feasibile first-tier selection. Sci. Total Environ. 421-422, 102-110. (doi: 10. 1016/j. scitotenv. 2012. 01. 039).
25. Kools SAE, Boxall ABA, Moltmann JF, Bryning G, Koschorreck J, Knacker T. 2008 A ranking of European veterinary medicines based on environmental risks. Integr. Environ. Assess. Manag. 4, 399-408. (doi: 10. 1897/IEAM_2008-002. 1).
26. Christen V, Hickmann S, Rechenberg B, Fent K. 2010 Highly active human pharmaceuticals in aquatic systems: a concept for their identification based on their mode of action. Aquat. Toxicol. 96, 167-181. (doi: 10. 1016/j. aquatox. 2009. 11. 021).
27. Schreiber R, Gündel U, Franz S, Küster A, Rechenberg B, Altenburger R. 2011 Using the fish plasma model for comparative hazard identification for pharmaceuticals in the environment by extrapolation from human therapeutic data. Regul. Toxicol. Pharmacol. 61, 261-275. (doi: 10. 1016/j. yrtph. 2011. 08. 006).
28. Nakamura Y, Yamamoto H, Sekizawa J, Kondo T, Hirai N, Tatrazako N. 2008 The effects of pH on fluoxetine in Japanese medaka (Oryzias latipes): acute toxicity in fish larvae and bioaccumulation in juvenile fish. Chemosphere 70, 865-873. (doi: 10. 1016/j. chemosphere. 2007. 06. 089).
29. Valenti TW, Perez-Hurtado P, Chambliss CK, Brooks BW. 2009 Aquatic toxicity of sertraline to Pimephales promelas at environmentally relevant surface water pH. Environ. Toxicol. Chem. 28, 2685-2694. (doi: 10. 1897/08-546. 1).
30. Babic S, Horvat AJM, Mutavdzic Pavlovic M, Katelan-Macan M. 2007 Determination of pKa values of active pharmaceutical ingredients. Trends Anal. Chem. 26. (doi: 10. 1016/j. trac. 2007. 09. 004).
31. Berninger JP, Du B, Connors KA, Eycheson SA, Kolkmeier MA, Prosser KN, Valenti TW, Chambliss K, Brooks BW. 2011 Effects of the antihistamine diphenhydramine on selected aquatic organisms. Environ. Toxicol. Chem. 30, 2065-2072. (doi: 10. 1002/etc. 590).